Should Alzheimer’s drugs be treated like all other drugs when it comes to Medicare coverage? The Alliance for Aging Research CEO Sue Peschin and BrainStorm host Meryl Comer dive into polling data that reveals most American voters, regardless of party, disagree with CMS’s policy that will limit access. Their conversation sheds light on how the coverage decision, if it stands, will create not only greater disparities, but also have wide-ranging implications on coverage for other disease-modifying therapies. This episode is sponsored by Eisai. Support the show